News & Updates

Nintedanib is the only antifibrotic approved in Hong Kong for progressive pulmonary fibrosis and systemic sclerosis–associated interstitial lung disease (ILD). Read further on how nintedanib slows lung function decline in connective tissue disease–associated ILD (CTD-ILD), as well as ERS/EULAR 2025 guideline recommendations on screening, diagnosis, monitoring, and treatment of CTD-ILD.

Systemic lupus erythematosus (SLE) patients with acute coronary syndrome (ACS) need a longer hospital stay and accrue higher charges, resulting in higher healthcare utilization, reports a study.

In patients with deficiency of adenosine deaminase 2 (DADA2) vasculitis, early age of onset and periodic illness are associated with disease-related damage, but prompt initiation of a tumour necrosis factor inhibitor (TNFi) may prevent complications and severe progression, suggests a study.

Treatment with LEVI-04—a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3—helps improve pain and function in patients with knee osteoarthritis, as shown in a phase II trial.

A 61-year-old female with a >20-year history of connective tissue disease–related pulmonary arterial hypertension (CTD-PAH) was admitted in June 2025. Despite being on triple therapy for PAH as well as prednisolone and cyclophospha­mide for systemic lupus erythematosus (SLE), her PAH remained uncontrolled. 

Patients with Sjögren’s disease (SjD) have a heightened risk of cancer, and this risk increase extends to their first-degree relatives, according to a study.

For patients with systemic lupus erythematosus (SLE) who are undergoing peritoneal dialysis, the risk of peritonitis development may increase with the use of gastric acid suppressants and glucocorticoids and in males, according to a retrospective study.

Gout does not contribute to an increased risk of overall dementia and may even be protective against Alzheimer's disease (AD) and cognitive impairment, according to the results of a systematic review and meta-analysis.